Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
暂无分享,去创建一个
L. Garraway | X. Mu | R. Sullivan | Judit Jané-Valbuena | J. McQuade | J. Wargo | A. Lazar | R. Amaria | S. Patel | P. Hwu | A. Reuben | C. Hudgens | M. Tetzlaff | K. Wani | S. Bahl | Kevin B. Kim | Guo Chen | Hong Jiang | Ali Amin-Mansour | Z. Cooper | J. Roszik | R. Bassett | W. Hwu | A. Diab | I. Glitza | Aron Y Joon | D. Panka | M. Davies | Lauren Simpson | Rosalind Mouton | C. Creasy
[1] Steven J. M. Jones,et al. Genomic Classification of Cutaneous Melanoma , 2015, Cell.
[2] D. Schadendorf,et al. BRAF inhibitor acquired resistance: A multicenter meta-analysis of the spectrum and clinical implications of resistance mechanisms. , 2015 .
[3] L. Chin,et al. Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. , 2015, The Journal of clinical investigation.
[4] Yuan Qi,et al. Clinical actionability enhanced through deep targeted sequencing of solid tumors. , 2015, Clinical chemistry.
[5] K. Flaherty,et al. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Utikal,et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.
[7] P. Ascierto,et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.
[8] Richard F. Kefford,et al. Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients , 2014, Clinical Cancer Research.
[9] A. Giobbie-Hurder,et al. Clinical Utility of a Blood-Based BRAFV600E Mutation Assay in Melanoma , 2014, Molecular Cancer Therapeutics.
[10] Gordon B Mills,et al. The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF. , 2014, Cancer research.
[11] G. Pupo,et al. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma , 2014, Molecular oncology.
[12] K. Flaherty,et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Shuxia Zhao,et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. , 2013, Cancer discovery.
[14] T. Graeber,et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. , 2013, The Journal of clinical investigation.
[15] K. Flaherty,et al. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] R. Sullivan,et al. BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma , 2013, Clinical Cancer Research.
[17] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[18] Michael A. Davies,et al. Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma , 2012, Clinical Cancer Research.
[19] S. Nelson,et al. Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance , 2012, Nature Communications.
[20] Tom Misteli,et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.
[21] Nikhil Wagle,et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] S. Nelson,et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.
[23] Damien Kee,et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. , 2010, Cancer cell.
[24] Marc Vidal,et al. COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation , 2010, Nature.
[25] Kam Y. J. Zhang,et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.
[26] V. Sondak,et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy , 2010, British Journal of Cancer.
[27] W. Sellers,et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition , 2009, Proceedings of the National Academy of Sciences.
[28] M. Okada,et al. [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.
[29] C. Sander,et al. V600EBRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway , 2009, Proceedings of the National Academy of Sciences.
[30] C. N. Coleman,et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. , 2003, Seminars in radiation oncology.
[31] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[32] A. Hauschild,et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.
[33] Antoni Ribas,et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. , 2014, Cancer discovery.
[34] Dennis C. Friedrich,et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. , 2014, Cancer discovery.
[35] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .